GEHC
NEUTRAL
$72.91
Live
GE HealthCare Technologies Inc. · NASDAQ
Target $91.74
(+25.8%)
$59.95
52W Range
$89.77
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 10, 2026
Market cap
$33.27B
P/E
16.2
ROE
22.4%
Profit margin
10.1%
Debt/Equity
0.99
Dividend yield
0.19%
AI Analysis
AI-powered fundamental assessment
Confidence
85%
GEHC presents a stark contrast between analyst optimism and deterministic fundamental health. The Piotroski F-Score of 3/9 indicates weak financial health, and the current price of $72.91 trades at a significant premium to both the Graham Number ($48.02) and the Intrinsic Value ($31.50). While the company maintains strong ROE (22.38%) and consistent earnings beats, the negative YoY earnings growth (-17.70%) and bearish technical trend suggest a period of instability. The stock is fundamentally overvalued based on deterministic models, though it remains cheaper than the broader healthcare sector average P/E.
Key Strengths
Strong Return on Equity (ROE) of 22.38%
Consistent track record of beating quarterly earnings estimates (3/4 last year)
Low P/E ratio (16.20) relative to the healthcare sector average (44.85)
Healthy gross margins of 39.98%
Positive revenue growth (7.10% YoY)
Key Risks
Weak Piotroski F-Score (3/9) signaling deteriorating fundamentals
Significant negative earnings growth (-17.70% YoY)
Current price is substantially higher than Graham and Intrinsic value estimates
Bearish technical trend (0/100)
Low dividend yield (0.19%) providing little income support
AI Fair Value Estimate
Based on comprehensive analysis
$48.02
-34.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
40
Moderate
30
50
65
25
30
AI Verdict
Overvalued with Weakening Fundamentals
Key drivers: Piotroski F-Score, Price-to-Intrinsic Value Gap, Earnings Growth Decline
Confidence
90%
Value
30/100
Trading at a premium to defensive fair value despite low sector-relative P/E.
Positives
- Low P/E compared to sector
Watchpoints
- Price far exceeds Graham Number ($48.02)
- Price far exceeds Intrinsic Value ($31.50)
Future
50/100
Revenue is growing, but profitability is contracting.
Positives
- Steady revenue growth
- Bullish analyst target price ($91.74)
Watchpoints
- Negative YoY earnings growth
- PEG ratio of 1.67 suggests overvaluation relative to growth
Past
65/100
Consistent operational execution (beats) but inconsistent long-term price performance.
Positives
- Strong history of earnings surprises
- Positive 1Y price change (+12.5%)
Watchpoints
- Negative 3Y price change (-9.0%)
Health
25/100
Deterministic health scores indicate significant fundamental weakness.
Positives
- Current ratio (1.37) is above 1.0
Watchpoints
- Piotroski F-Score of 3/9 is categorized as Weak
- Debt/Equity near 1.0
Dividend
30/100
Dividend is symbolic rather than a primary value driver.
Positives
- Very low payout ratio (3.08%) allows for future increases
Watchpoints
- Negligible yield (0.19%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$72.91
Analyst Target
$91.74
Upside/Downside
+25.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GEHC and closest competitors.
Updated 2026-04-09
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GEHC
GE HealthCare Technologies Inc.
Primary
|
+22.2% | -9.0% | +12.5% | -1.6% | +0.3% | +3.6% |
|
A
Agilent Technologies, Inc.
Peer
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
BIIB
Biogen Inc.
Peer
|
-34.2% | -34.1% | +34.0% | +30.9% | -2.5% | -0.3% |
|
ALNY
Alnylam Pharmaceuticals, Inc.
Peer
|
+114.5% | +67.5% | +29.6% | -32.7% | -2.8% | -2.3% |
GEH
GE HealthCare Technologies Inc.
Primary
5Y
+22.2%
3Y
-9.0%
1Y
+12.5%
6M
-1.6%
1M
+0.3%
1W
+3.6%
A
Agilent Technologies, Inc.
Peer
5Y
+11.4%
3Y
-11.3%
1Y
-10.7%
6M
+12.8%
1M
-2.2%
1W
-3.3%
ALC
Alcon Inc.
Peer
5Y
+8.8%
3Y
+9.9%
1Y
-9.6%
6M
-12.6%
1M
+0.1%
1W
+1.6%
BII
Biogen Inc.
Peer
5Y
-34.2%
3Y
-34.1%
1Y
+34.0%
6M
+30.9%
1M
-2.5%
1W
-0.3%
ALN
Alnylam Pharmaceuticals, Inc.
Peer
5Y
+114.5%
3Y
+67.5%
1Y
+29.6%
6M
-32.7%
1M
-2.8%
1W
-2.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
16.2
Forward P/E
13.1
PEG Ratio
1.67
P/B Ratio
3.2
P/S Ratio
1.61
EV/Revenue
1.91
EV/EBITDA
10.82
Market Cap
$33.27B
Profitability
Profit margins and return metrics
Profit Margin
10.1%
Operating Margin
15.72%
Gross Margin
39.98%
ROE
22.38%
ROA
5.47%
Growth
Revenue and earnings growth rates
Revenue Growth
+7.1%
Earnings Growth
-17.7%
Q/Q Revenue Growth
+7.13%
Q/Q Earnings Growth
-18.3%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.99
Moderate
Current Ratio
1.37
Good
Quick Ratio
1.01
Good
Cash/Share
$9.86
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$5.7B
Gross Margin
39.7%
Op. Margin
14.5%
Net Margin
10.3%
Total Assets
$36.9B
Liabilities
$26.3B
Equity
$10.4B
Debt/Equity
2.53x
Operating CF
$1.1B
CapEx
$-0.1B
Free Cash Flow
$0.9B
FCF Yield
87%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-02-04
$1.44
+3.0% surprise
2025-10-29
$1.07
+2.2% surprise
2025-07-30
$1.06
+15.4% surprise
Healthcare Sector Comparison
Comparing GEHC against 205 companies in the Healthcare sector
(17 bullish, 70 neutral, 118 bearish)
P/E Ratio
16.2
This Stock
vs
43.63
Sector Avg
-62.9%
(Discount)
Return on Equity (ROE)
22.38%
This Stock
vs
-42.45%
Sector Avg
-152.7%
(Below Avg)
Profit Margin
10.1%
This Stock
vs
-18.49%
Sector Avg
-154.6%
(Weaker)
Debt to Equity
0.99
This Stock
vs
4.76
Sector Avg
-79.3%
(Less Debt)
Revenue Growth
7.1%
This Stock
vs
106.86%
Sector Avg
-93.4%
(Slower)
Current Ratio
1.37
This Stock
vs
3.53
Sector Avg
-61.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GEHC
GE HealthCare Technologies Inc.
|
NEUTRAL | $33.27B | 16.2 | 22.4% | 10.1% | $72.91 | |
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | Compare |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | Compare |
|
BIIB
Biogen Inc.
|
NEUTRAL | $26.91B | 20.83 | 7.4% | 13.1% | $183.33 | Compare |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
BEARISH | $41.57B | 135.09 | 73.3% | 8.4% | $313.41 | Compare |
GEHC
GE HealthCare...
NEUTRAL
Mkt Cap
$33.3B
P/E
16.2
ROE
22.4%
Price
$72.91
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | LOBO KEVIN A | Director | Stock Award | 777 | - |
| 2026-03-02 | KASS-HOUT TAHA | Chief Technology Officer | Stock Award | 13,254 | - |
| 2026-03-02 | NEWCOMB GEORGE A. | Officer | Stock Award | 1,309 | - |
| 2026-03-02 | RACKLIFFE PHILIP | Officer | Stock Award | 9,356 | - |
| 2026-03-02 | ARDUINI PETER J | Chief Executive Officer | Stock Award | 49,120 | - |
| 2026-03-02 | JIMENEZ FRANK R | General Counsel | Stock Award | 10,915 | - |
| 2026-03-02 | SACCARO JAMES | Chief Financial Officer | Stock Award | 12,475 | - |
| 2026-03-02 | HOLTON ADAM Y | Officer | Stock Award | 5,457 | - |
| 2026-03-02 | BANKES JEANNETTE | Officer | Stock Award | 6,861 | - |
| 2026-03-02 | ROTT ROLAND | Officer | Stock Award | 8,576 | - |
| 2026-03-02 | O'NEILL KEVIN MICHAEL | Officer | Stock Award | 6,549 | - |
| 2026-02-12 | NEWCOMB GEORGE A. | Officer | Stock Award | 2,523 | - |
| 2026-02-12 | RACKLIFFE PHILIP | Officer | Stock Award | 3,154 | - |
| 2026-02-12 | ARDUINI PETER J | Chief Executive Officer | Stock Award | 74,908 | - |
| 2026-02-12 | JIMENEZ FRANK R | General Counsel | Stock Award | 22,078 | - |
LOBO KEVIN A
Director
2026-03-13
777 shares
KASS-HOUT TAHA
Chief Technology Officer
2026-03-02
13,254 shares
NEWCOMB GEORGE A.
Officer
2026-03-02
1,309 shares
RACKLIFFE PHILIP
Officer
2026-03-02
9,356 shares
ARDUINI PETER J
Chief Executive Officer
2026-03-02
49,120 shares
JIMENEZ FRANK R
General Counsel
2026-03-02
10,915 shares
SACCARO JAMES
Chief Financial Officer
2026-03-02
12,475 shares
HOLTON ADAM Y
Officer
2026-03-02
5,457 shares
BANKES JEANNETTE
Officer
2026-03-02
6,861 shares
ROTT ROLAND
Officer
2026-03-02
8,576 shares
O'NEILL KEVIN MICHAEL
Officer
2026-03-02
6,549 shares
NEWCOMB GEORGE A.
Officer
2026-02-12
2,523 shares
RACKLIFFE PHILIP
Officer
2026-02-12
3,154 shares
ARDUINI PETER J
Chief Executive Officer
2026-02-12
74,908 shares
JIMENEZ FRANK R
General Counsel
2026-02-12
22,078 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
19 analysts
Goldman Sachs
2026-04-09
Buy
Buy
Evercore ISI Group
2026-04-06
Outperform
Outperform
BTIG
2026-03-19
Buy
Buy
Citigroup
2026-03-11
Neutral
Neutral
BTIG
2026-02-09
Buy
Buy
Barclays
2026-02-06
Equal-Weight
Equal-Weight
Stifel
2026-02-05
Buy
Buy
Evercore ISI Group
2026-02-05
Outperform
Outperform
Wells Fargo
2026-02-05
Overweight
Overweight
Morgan Stanley
2026-02-05
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning GEHC from our newsroom.
Newest → oldest
No matching news yet.